{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:47:43Z","timestamp":1770745663907,"version":"3.49.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Ionophore antibiotics were reported to selectively kill cancer stem cells and to overcome multidrug resistance, but mechanistic studies of the significance of drug transporters for treatment with these compounds are lacking. We applied chemosensitivity testing of well-characterized human cancer cell lines to elaborate on whether drug transporters are involved in protection from the cytotoxic effects of the ionophore antibiotics salinomycin and nigericin. Our experiments demonstrated that ionophore antibiotics were ineffective against both stem-like ovarian cancer side population cells (expressing either ABCB1 or ABCG2) and K562\/Dox-H1 cells, which constitute a genetically defined model system for ABCB1 expression. Considering that cancer stem cells often express high levels of drug transporters, we deduced from our results that ionophore antibiotics are less suited to cancer stem cell-targeted treatment than previously thought.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Significance<\/jats:title>\n                  <jats:p>Ionophore antibiotics such as salinomycin have repeatedly been shown to target cancer stem and progenitor cells from various tumor entities. Meanwhile, cancer stem cell (CSC)-selective toxicity of ionophore antibiotics seems to be a commonly accepted concept that is about to encourage their clinical testing. This study provides data that challenge the concept of targeted elimination of CSC by ionophore antibiotics. Stem-like ovarian cancer side population (SP) cells expressing high levels of ABC drug transporters are shown to largely resist the cytotoxic effects of salinomycin and nigericin. Furthermore, using a small interfering RNA-based knockdown model specific for ABCB1, this study demonstrates that ABC drug transporters are indeed causally involved in mediating protection from ionophore antibiotics. Considering that it is a hallmark of CSCs to exhibit drug resistance conferred by ABC drug transporters, it must be deduced from these results that CSCs may also be protected from ionophore antibiotics by means of drug-transporter mediated efflux.<\/jats:p>\n               <\/jats:sec>","DOI":"10.5966\/sctm.2015-0054","type":"journal-article","created":{"date-parts":[[2015,7,2]],"date-time":"2015-07-02T04:10:57Z","timestamp":1435810257000},"page":"1028-1032","source":"Crossref","is-referenced-by-count":32,"title":["Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics"],"prefix":"10.1093","volume":"4","author":[{"given":"Maximilian","family":"Boesch","sequence":"first","affiliation":[{"name":"Institute of Immunobiology, St. Gallen, Switzerland"},{"name":"Tyrolean Cancer Research Institute, Innsbruck, Austria"},{"name":"Internal Medicine V, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain G.","family":"Zeimet","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Rumpold","sequence":"additional","affiliation":[{"name":"Internal Medicine I, Klinikum der Barmherzigen Schwestern Linz, Linz, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guenther","family":"Gastl","sequence":"additional","affiliation":[{"name":"Internal Medicine V, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sieghart","family":"Sopper","sequence":"additional","affiliation":[{"name":"Tyrolean Cancer Research Institute, Innsbruck, Austria"},{"name":"Internal Medicine V, Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Wolf","sequence":"additional","affiliation":[{"name":"Tyrolean Cancer Research Institute, Innsbruck, Austria"},{"name":"Internal Medicine V, Medical University Innsbruck, Innsbruck, Austria"},{"name":"Medical Clinic III, Oncology, Hematology and Rheumatology, University Clinic Bonn, Bonn, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,7,1]]},"reference":[{"key":"2021122704324067500_R1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/0006-291X(75)90490-8","article-title":"Salinomycin: A new monovalent cation ionophore","volume":"66","author":"Mitani","year":"1975","journal-title":"Biochem Biophys Res Commun"},{"key":"2021122704324067500_R2","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/ps\/78.12.1681","article-title":"The effect of flavophospholipol (Flavomycin) and salinomycin sodium (Sacox) on the excretion of Clostridium perfringens, Salmonella enteritidis, and Campylobacter jejuni in broilers after experimental infection","volume":"78","author":"Bolder","year":"1999","journal-title":"Poult Sci"},{"key":"2021122704324067500_R3","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cell.2009.06.034","article-title":"Identification of selective inhibitors of cancer stem cells by high-throughput screening","volume":"138","author":"Gupta","year":"2009","journal-title":"Cell"},{"key":"2021122704324067500_R4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.canlet.2011.07.016","article-title":"Salinomycin inhibits osteosarcoma by targeting its tumor stem cells","volume":"311","author":"Tang","year":"2011","journal-title":"Cancer Lett"},{"key":"2021122704324067500_R5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/bjc.2011.530","article-title":"Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress","volume":"106","author":"Ketola","year":"2012","journal-title":"Br J Cancer"},{"key":"2021122704324067500_R6","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1186\/1471-2407-12-556","article-title":"Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt","volume":"12","author":"Kuo","year":"2012","journal-title":"BMC Cancer"},{"key":"2021122704324067500_R7","doi-asserted-by":"crossref","first-page":"714","DOI":"10.4161\/auto.23997","article-title":"Inhibition of the autophagic flux by salinomycin in breast cancer stem-like\/progenitor cells interferes with their maintenance","volume":"9","author":"Yue","year":"2013","journal-title":"Autophagy"},{"key":"2021122704324067500_R8","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ygyno.2013.03.005","article-title":"The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells","volume":"129","author":"Kusunoki","year":"2013","journal-title":"Gynecol Oncol"},{"key":"2021122704324067500_R9","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.bbrc.2009.10.042","article-title":"Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells","volume":"390","author":"Fuchs","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"key":"2021122704324067500_R10","doi-asserted-by":"crossref","first-page":"13253","DOI":"10.1073\/pnas.1110431108","article-title":"Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells","volume":"108","author":"Lu","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122704324067500_R11","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc1590","article-title":"Tumour stem cells and drug resistance","volume":"5","author":"Dean","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"2021122704324067500_R12","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.bbrc.2010.03.138","article-title":"Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells","volume":"394","author":"Fuchs","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"2021122704324067500_R13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcmd.2010.03.008","article-title":"The cancer stem cell selective inhibitor salinomycin is a p-glycoprotein inhibitor","volume":"45","author":"Riccioni","year":"2010","journal-title":"Blood Cells Mol Dis"},{"key":"2021122704324067500_R14","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4149\/neo_2012_094","article-title":"Ovarian cancer stem cells","volume":"59","author":"Zeimet","year":"2012","journal-title":"Neoplasma"},{"key":"2021122704324067500_R15","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/(SICI)1097-0215(19960917)67:6<826::AID-IJC12>3.0.CO;2-#","article-title":"Different effects of interferons, interleukin-1beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells","volume":"67","author":"Marth","year":"1996","journal-title":"Int J Cancer"},{"key":"2021122704324067500_R16","first-page":"4970","article-title":"Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice","volume":"45","author":"B\u00e9nard","year":"1985","journal-title":"Cancer Res"},{"key":"2021122704324067500_R17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.exphem.2005.03.014","article-title":"RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines","volume":"33","author":"Rumpold","year":"2005","journal-title":"Exp Hematol"},{"key":"2021122704324067500_R18","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.18632\/oncotarget.2053","article-title":"The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics","volume":"5","author":"Boesch","year":"2014","journal-title":"Oncotarget"},{"key":"2021122704324067500_R19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/cyto.a.22038","article-title":"DyeCycle Violet used for side population detection is a substrate of P-glycoprotein","volume":"81","author":"Boesch","year":"2012","journal-title":"Cytometry A"},{"key":"2021122704324067500_R20","doi-asserted-by":"crossref","first-page":"11154","DOI":"10.1073\/pnas.0603672103","article-title":"Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness","volume":"103","author":"Szotek","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122704324067500_R21","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1158\/0008-5472.CAN-07-6341","article-title":"The side population of ovarian cancer cells is a primary target of IFN-\u03b1 antitumor effects","volume":"68","author":"Moserle","year":"2008","journal-title":"Cancer Res"},{"key":"2021122704324067500_R22","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/sj.bjc.6605626","article-title":"Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant","volume":"102","author":"Hu","year":"2010","journal-title":"Br J Cancer"},{"key":"2021122704324067500_R23","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1158\/1535-7163.MCT-10-0788","article-title":"Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2","volume":"10","author":"Rizzo","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"2021122704324067500_R24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nrd4253","article-title":"Tackling the cancer stem cells - what challenges do they pose?","volume":"13","author":"Pattabiraman","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"2021122704324067500_R25","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1158\/1535-7163.MCT-11-1040","article-title":"DNA damage repair pathways in cancer stem cells","volume":"11","author":"Maugeri-Sacc\u00e0","year":"2012","journal-title":"Mol Cancer Ther"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.5966%2Fsctm.2015-0054","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.5966%2Fsctm.2015-0054","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/4\/9\/1028\/41863939\/stcltm_4_9_1028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/4\/9\/1028\/41863939\/stcltm_4_9_1028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:49:38Z","timestamp":1642560578000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/4\/9\/1028-1032\/6397267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,1]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,7,1]]},"published-print":{"date-parts":[[2015,9,1]]}},"URL":"https:\/\/doi.org\/10.5966\/sctm.2015-0054","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,9,1]]},"published":{"date-parts":[[2015,7,1]]}}}